BRPI0813355A2 - Compostos de quinazolinona e métodos de uso dos mesmos - Google Patents

Compostos de quinazolinona e métodos de uso dos mesmos

Info

Publication number
BRPI0813355A2
BRPI0813355A2 BRPI0813355-7A2A BRPI0813355A BRPI0813355A2 BR PI0813355 A2 BRPI0813355 A2 BR PI0813355A2 BR PI0813355 A BRPI0813355 A BR PI0813355A BR PI0813355 A2 BRPI0813355 A2 BR PI0813355A2
Authority
BR
Brazil
Prior art keywords
methods
quinazolinone compounds
quinazolinone
compounds
Prior art date
Application number
BRPI0813355-7A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jifeng Liu
Syed M Ali
Mark A Ashwell
Ping Ye
Yousheng Guan
Shi-Chung Ng
Rocio Palma
Dan Yohannes
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BRPI0813355A2 publication Critical patent/BRPI0813355A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0813355-7A2A 2007-06-22 2008-06-19 Compostos de quinazolinona e métodos de uso dos mesmos BRPI0813355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94583807P 2007-06-22 2007-06-22
PCT/US2008/067571 WO2009002808A2 (en) 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0813355A2 true BRPI0813355A2 (pt) 2014-12-30

Family

ID=39846620

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813355-7A2A BRPI0813355A2 (pt) 2007-06-22 2008-06-19 Compostos de quinazolinona e métodos de uso dos mesmos

Country Status (13)

Country Link
US (1) US8232285B2 (cg-RX-API-DMAC7.html)
EP (1) EP2173724B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010530885A (cg-RX-API-DMAC7.html)
KR (1) KR20100024494A (cg-RX-API-DMAC7.html)
CN (1) CN101801937A (cg-RX-API-DMAC7.html)
AU (1) AU2008268613A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813355A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704282A1 (cg-RX-API-DMAC7.html)
IL (1) IL202740A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013815A (cg-RX-API-DMAC7.html)
TW (1) TW200918069A (cg-RX-API-DMAC7.html)
WO (1) WO2009002808A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000183B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242988B2 (en) * 2010-04-19 2013-02-07 Sri International Compositions and method for the treatment of multiple myeloma
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US20150132575A1 (en) * 2013-11-14 2015-05-14 Honeywell International Inc. Luminescent fibers, articles including the same, and methods of forming the same
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US20210188843A1 (en) * 2018-05-11 2021-06-24 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Quinoline compounds and their preparation and use as antimalarial agents
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723432A (en) 1968-11-12 1973-03-27 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
IL89167A (en) 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5380746A (en) 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5591842A (en) 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
JP2831467B2 (ja) 1992-03-12 1998-12-02 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下４▼−受容体アンタゴニストとしての縮合インドール誘導体
WO1993018765A1 (en) 1992-03-20 1993-09-30 The Wellcome Foundation Limited Indole derivatives with antiviral activity
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995030682A1 (en) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
US5559228A (en) 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
IL126272A0 (en) 1996-03-20 1999-05-09 Lilly Co Eli Synthesis of indolylmaleimides
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
NZ334030A (en) 1996-08-23 2000-08-25 Lilly Co Eli Synthesis of bisindolylmalimides
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5859261A (en) 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6184377B1 (en) 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
CN1320123A (zh) 1998-07-30 2001-10-31 日本烟草产业株式会社 二取代马来酰亚胺化合物及其医药用途
WO2000047575A1 (en) 1999-02-09 2000-08-17 Sagami Chemical Research Center Pyrrole derivatives and cell death inhibitors
PL203998B1 (pl) 1999-10-27 2009-11-30 Cytokinetics Inc Nowy związek chinazolinowy, zastosowanie związku chinazolinowego, sposób jego otrzymywania i kompozycja farmaceutyczna zawierająca związek chinazolinowy
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
ATE267194T1 (de) 1999-12-16 2004-06-15 Lilly Co Eli Medikamente geeignet zur behandlung von proliferativen erkrankungen
WO2001044247A2 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US20030087949A1 (en) 2000-03-30 2003-05-08 Mikiko Sodeoka Indolylpyrrole derivatives and cell death inhibitors
HUP0302002A3 (en) 2000-05-11 2007-02-28 Consejo Superior Investigacion Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them
WO2002002593A2 (en) 2000-06-29 2002-01-10 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESINS
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003066808A2 (en) 2002-01-23 2003-08-14 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
EP1480980A4 (en) 2002-02-15 2005-04-20 Cytokinetics Inc SYNTHESIS OF QUINAZOLINONES
EP1483265B1 (en) 2002-03-05 2006-11-22 Eli Lilly And Company Purine derivatives as kinase inhibitors
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
EP1537089A4 (en) * 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
US20070059697A1 (en) 2003-04-15 2007-03-15 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2004110990A2 (en) 2003-05-15 2004-12-23 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
DE602004019919D1 (de) 2003-06-06 2009-04-23 Genentech Inc Modulation der wechselwirkung zwischen hgf-beta-kette und c-met
ATE451115T1 (de) 2003-07-07 2009-12-15 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2006044869A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
SI1846406T1 (sl) 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CN101189023B (zh) 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses

Also Published As

Publication number Publication date
IL202740A0 (en) 2010-06-30
ZA201000183B (en) 2011-03-30
US8232285B2 (en) 2012-07-31
EP2173724B1 (en) 2012-12-05
MX2009013815A (es) 2010-03-01
EP2173724A2 (en) 2010-04-14
CN101801937A (zh) 2010-08-11
JP2010530885A (ja) 2010-09-16
KR20100024494A (ko) 2010-03-05
AU2008268613A1 (en) 2008-12-31
TW200918069A (en) 2009-05-01
CA2704282A1 (en) 2008-12-31
WO2009002808A3 (en) 2009-07-23
US20090130097A1 (en) 2009-05-21
WO2009002808A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
BRPI0813355A2 (pt) Compostos de quinazolinona e métodos de uso dos mesmos
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
BRPI0820457A2 (pt) Fluidos de ruptura e métodos de uso dos mesmos
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0821499A2 (pt) Artigos de filtração de fluído e métodos de preparo e uso dos mesmos
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0909077A2 (pt) Artigos multicamadas e métodos de preparo e uso dos mesmos
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso
BRPI0907236A2 (pt) inibidores de proteína quinase e uso dos mesmos
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.